The Effect of Neurokinin1 Receptor Blockade on Territorial Aggression and in a Model of Violent Aggression

Biological Psychiatry

Volumn 63, Issue 3, 2008, Pages 271-278

  Halasz, Jozsef ^a   Toth, Mate ^a   Mikics, Eva ^a   Hrabovszky, Erik ^a   Barsy, Boglarka ^a   Barsvari, Beata ^a   Haller, Jozsef ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Aggression; amygdala; glucocorticoid; NK1 receptor; Substance P; violence

Indexed keywords

L 703 606; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; PROTEIN C FOS; UNCLASSIFIED DRUG;

AGGRESSION; AMYGDALOID NUCLEUS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTISOCIAL BEHAVIOR; ANXIETY; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DRUG EFFECT; LOCOMOTION; MALE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SOCIAL PSYCHOLOGY; VIOLENCE;

ADRENALECTOMY; AGGRESSION; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CORTICOSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; MODELS, ANIMAL; NEURONS; PROTO-ONCOGENE PROTEINS C-FOS; QUINUCLIDINES; RATS; RATS, WISTAR; RECEPTORS, NEUROKININ-1; TERRITORIALITY;

EID: 37849054548     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2007.04.022     Document Type: Article

References (56)

1. Saffroy M., Torrens Y., Glowinski J., and Beaujouan J.C. Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: Comparison with NK1 and NK3 binding sites. Neuroscience 116 (2003) 761-773
2. Tsuchida K., Shigemoto R., Yokota Y., and Nakanishi S. Tissue distribution and quantitation of the mRNAs for three rat tachykinin receptors. Eur J Biochem 193 (1990) 751-757
3. Yip J., and Chahl L.A. Localization of tachykinin receptors and Fos-like immunoreactivity induced by substance P in guinea-pig brain. Clin Exp Pharmacol Physiol 27 (2000) 943-946
4. Czeh B., Fuchs E., and Simon M. NK1 receptor antagonists under investigation for the treatment of affective disorders. Expert Opin Investig Drugs 15 (2006) 479-486 Review
5. File S.E. NKP608, an NK1 receptor antagonist, has an anxiolytic action in the social interaction test in rats. Psychopharmacology (Berl) 152 (2000) 105-109
6. Rupniak N.M., Carlson E.J., Webb J.K., Harrison T., Porsolt R.D., Roux S., et al. Comparison of the phenotype of NK1R-/- mice with pharmacological blockade of the substance P (NK1) receptor in assays for antidepressant and anxiolytic drugs. Behav Pharmacol 12 (2001) 497-508
7. Santarelli L., Gobbi G., Blier P., and Hen R. Behavioral and physiologic effects of genetic or pharmacologic inactivation of the substance P receptor (NK1). J Clin Psychiatry 63 suppl 11 (2002) 11-17 Review
8. Shaikh M.B., Steinberg A., and Siegel A. Evidence that substance P is utilized in medial amygdaloid facilitation of defensive rage behavior in the cat. Brain Res 625 (1993) 283-294
9. Yao R., Rameshwar P., Gregg T., and Siegel A. Co-localization of NK(1)-receptor mRNA with glutamate immunopositivity in cat hypothalamic neurons by the combination of in situ hybridization and immunohistochemistry. Brain Res Brain Res Protoc 7 (2001) 154-161
10. De Felipe C., Herrero J.F., O'Brien J.A., Palmer J.A., Doyle C.A., Smith A.J., et al. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature 392 (1998) 394-397
11. Dolan M., Anderson I.M., and Deakin J.F. Relationship between 5-HT function and impulsivity and aggression in male offenders with personality disorders. Br J Psychiatry 178 (2001) 352-359
12. McBurnett K., Lahey B.B., Rathouz P.J., and Loeber R. Low salivary cortisol and persistent aggression in boys referred for disruptive behavior. Arch Gen Psychiatry 57 (2000) 38-43
13. Virkkunen M. Urinary free cortisol secretion in habitually violent offenders. Acta Psychiatr Scand 72 (1985) 40-44
14. Brennan P.A., Raine A., Schulsinger F., Kirkegaard-Sorensen L., Knop J., Hutchings B., et al. Psychophysiological protective factors for male subjects at high risk for criminal behavior. Am J Psychiatry 154 (1997) 853-855
15. Raine A. Autonomic nervous system factors underlying disinhibited, antisocial, and violent behavior. Biosocial perspectives and treatment implications. Ann N Y Acad Sci 794 (1996) 46-59
16. Raine A. Annotation: The role of prefrontal deficits, low autonomic arousal, and early health factors in the development of antisocial and aggressive behavior in children. J Child Psychol Psychiatry 43 (2002) 417-434
17. Woodman D., and Hinton J. Catecholamine balance during stress anticipation: An abnormality in maximum security hospital patients. J Psychosom Res 22 (1978) 477-483
18. Sareen J., Stein M.B., Cox B.J., and Hassard S.T. Understanding comorbidity of anxiety disorders with antisocial behavior: Findings from two large community surveys. J Nerv Ment Dis 192 (2004) 178-186
19. Haller J., van de Schraaf J., and Kruk M.R. Deviant forms of aggression in glucocorticoid hyporeactive rats: A model for 'pathological' aggression?. J Neuroendocrinol 13 (2001) 102-107
20. Haller J., Halasz J., Mikics E., and Kruk M.R. Chronic glucocorticoid deficiency-induced abnormal aggression, autonomic hypoarousal, and social deficit in rats. J Neuroendocrinol 16 (2004) 550-557
21. Haller J., Mikics E., Halasz J., and Toth M. Mechanisms differentiating normal from abnormal aggression: glucocorticoids and serotonin. Eur J Pharmacol 526 (2005) 89-100 Review
22. Haller J., and Kruk M.R. Normal and abnormal aggression: Human disorders and novel laboratory models. Neurosci Biobehav Rev 30 (2006) 292-303 Review
23. Fava M. Psychopharmacologic treatment of pathologic aggression. Psychiatr Clin North Am 20 (1997) 427-451
24. Goedhard L.E., Stolker J.J., Heerdink E.R., Nijman H.L., Olivier B., and Egberts T.C. Pharmacotherapy for the treatment of aggressive behavior in general adult psychiatry: A systematic review. J Clin Psychiatry 67 (2006) 1013-1024 Review
25. Herrmann N. Recommendations for the management of behavioral and psychological symptoms of dementia. Can J Neurol Sci 28 (2001) S96-S107
26. Flint A.J., and van Reekum R. The pharmacologic treatment of Alzheimer's disease: A guide for the general psychiatrist. Can J Psychiatry 43 (1998) 689-697
27. Pabis D.J., and Stanislav S.W. Pharmacotherapy of aggressive behavior. Ann Pharmacother 30 (1996) 278-287
28. Bassarath L. Medication strategies in childhood aggression. Can J Psychiatry 48 (2003) 367-373
29. Coccaro E.F., Kavoussi R.J., and Hauger R.L. Serotonin function and antiaggressive response to fluoxetine: A pilot study. Biol Psychiatry 42 (1997) 546-552
30. Kutcher S.P., Marton P., and Korenblum M. Relationship between psychiatric illness and conduct disorder in adolescents. Can J Psychiatry 34 (1989) 526-529
31. Pine D.S., and Cohen E. Therapeutics of aggression in children. Paediatr Drugs 1 (1999) 183-197
32. Cascieri M.A., Ber E., Fong T.M., Sadowski S., Bansal A., Swain C., et al. Characterization of the binding of a potent, selective, radioiodinated antagonist to the human neurokinin-1 receptor. Mol Pharmacol 42 (1992) 458-463
33. Haddjeri N., and Blier P. Sustained blockade of neurokinin-1 receptors enhances serotonin neurotransmission. Biol Psychiatry 50 (2001) 191-199
34. MacLennan K.M., Smith P.F., and Darlington C.L. Adrenalectomy-induced neuronal degeneration. Prog Neurobiol 54 (1998) 481-498
35. Lammers J.H., Kruk M.R., Meelis W., and van der Poel A.M. Hypothalamic substrates for brain stimulation-induced attack, teeth-chattering and social grooming in the rat. Brain Res 449 (1988) 311-327
36. Ogawa S., Chester A.E., Hewitt S.C., Walker V.R., Gustafsson J.A., Smithies O., et al. Abolition of male sexual behaviors in mice lacking estrogen receptors alpha and beta (alpha beta ERKO). Proc Natl Acad Sci U S A 97 (2000) 14737-14741
37. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. 4th ed. (1998), Academic Press, San Diego
38. Halasz J., Liposits Z., Kruk M.R., and Haller J. Neural background of glucocorticoid dysfunction-induced abnormal aggression in rats: Involvement of fear- and stress-related structures. Eur J Neurosci 15 (2002) 561-569
39. Halasz J., Tóth M., Kalló I., Liposits Z., and Haller J. The activation of prefrontal cortical neurons in aggression-A double labeling study. Behav Brain Res 175 (2006) 166-175
40. Kruk M.R. Ethology and pharmacology of hypothalamic aggression in the rat. Neurosci Biobehav Rev 15 (1991) 527-538 Review
41. Hrabovszky E., Halasz J., Meelis W., Kruk M.R., Liposits Z., and Haller J. Neurochemical characterization of hypothalamic neurons involved in attack behavior: Glutamatergic dominance and co-expression of thyrotropin-releasing hormone in a subset of glutamatergic neurons. Neuroscience 133 (2005) 657-666
42. Siegel A., Roeling T.A., Gregg T.R., and Kruk M.R. Neuropharmacology of brain-stimulation-evoked aggression. Neurosci Biobehav Rev 23 (1999) 359-389 Review
43. Fazel S., and Danesh J. Serious mental disorder in 23000 prisoners: A systematic review of 62 surveys. Lancet 359 (2002) 545-550 Review
44. Ekselius L., Tillfors M., Furmark T., and Fredrikson M. Personality disorders in the general population: DSM-IV and ICD_10 defined prevalence as related to sociodemographic profile. Pers Individ Differ 30 (2001) 311-320
45. Eronen M., Angermeyer M.C., and Schulze B. The psychiatric epidemiology of violent behaviour. Soc Psychiatry Psychiatr Epidemiol 33 (1998) S13-S23
46. Moran P. The epidemiology of antisocial personality disorder. Soc Psychiatry Psychiatr Epidemiol 34 (1999) 231-242
47. Harris G.T. The relationship between neuroleptic drug dose and the performance of psychiatric patients in a maximum security token economy program. J Behav Ther Exp Psychiatry 20 (1989) 57-67
48. Kazdin A.E. Treatments for aggressive and antisocial children. Child Adolesc Psychiatr Clin N Am 9 (2000) 841-858
49. Kunz M., Yates K.F., Czobor P., Rabinowitz S., Lindenmayer J.P., and Volavka J. Course of patients with histories of aggression and crime after discharge from a cognitive-behavioral program. Psychiatr Serv 55 (2004) 654-659
50. Reeves R.R., Struve F.A., and Patrick G. Auditory and visual P300 evoked potentials do not predict response to valproate treatment of aggression in patients with borderline and antisocial personality disorders. Clin EEG Neurosci 36 (2005) 49-51
51. Reid W.H., and Gacono C. Treatment of antisocial personality, psychopathy, and other characterologic antisocial syndromes. Behav Sci Law 18 (2000) 647-662
52. Timmerman I.G., and Emmelkamp P.M. The effects of cognitive-behavioral treatment for forensic inpatients. Int J Offender Ther Comp Criminol 49 (2005) 590-606
53. Haller J., Toth M., and Halasz J. The activation of raphe serotonergic neurons in normal and hypoarousal-driven aggression: A double labeling study in rats. Behav Brain Res 161 (2005) 88-94
54. Haller J., Horvath Z., and Bakos N. The effect of buspirone on normal and hypoarousal-driven abnormal aggression in rats. Prog Neuropsychopharmacol Biol Psychiatry 31 (2007) 27-31
55. Fu Q., Heath A.C., Bucholz K.K., Nelson E., Goldberg J., Lyons M.J., et al. Shared genetic risk of major depression, alcohol dependence, and marijuana dependence: Contribution of antisocial personality disorder in men. Arch Gen Psychiatry 59 (2002) 1125-1132
56. Goodwin R.D., and Hamilton S.P. Lifetime comorbidity of antisocial personality disorder and anxiety disorders among adults in the community. Psychiatry Res 117 (2003) 159-166